ArticleFrontiers in immunology2026
HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) can induce severe immune-related adverse events (irAEs), including type 1 diabetes (ICI-T1D) and interstitial lung disease (ICI-ILD); however, predictive genetic markers have not yet been fully elucidated. Accordingly, this study aimed to identify genetic polymorphisms associated with susceptibility to nivolumab-induced ICI-T1D and ICI-ILD. To address this, whole-genome sequencing using next-generation sequencing was performed on genomic DNA obtained from patients recruited from multiple centers nationwide who developed ICI-T1D (n = 14), ICI-ILD (n = 58), or no irAEs (ICI-Control, n = 72) after initiation of nivolumab therapy, followed by a genome-wide association study (GWAS). The primary GWAS identified an association signal within the HLA region on chromosome 6 in the comparison between the ICI-T1D and ICI-Control groups, whereas no significant associations were detected in analyses involving the ICI-ILD group. This signal was accompanied by an increased rate of missing genotypes, most prominently around the HLA-DRB5 locus, suggesting underlying structural and haplotypic complexity within the HLA-DR region that cannot be fully resolved by reference genome-based short-read analysis alone, leading to a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.